Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: A prospective study

Blood

Volumn 113, Issue 22, 2009, Pages 5412-5417

  Landgren, Ola ^a   Kyle, Robert A ^b   Pfeiffer, Ruth M ^a   Katzmann, Jerry A ^b   Caporaso, Neil E ^a   Hayes, Richard B ^a   Dispenzieri, Angela ^b   Kumar, Shaji ^b   Clark, Raynell J ^b   Baris, Dalsu ^a   Hoover, Robert ^a   Rajkumar, S Vincent ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PARAPROTEIN; IMMUNOGLOBULIN; M PROTEINS (MYELOMA); M-PROTEINS (MYELOMA);

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER RISK; CANCER SCREENING; CLINICAL ASSESSMENT; CONCENTRATION (PARAMETERS); DISEASE COURSE; ELECTROPHORESIS; FEMALE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; PARAPROTEINEMIA; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; BLOOD; CANCER DIAGNOSIS; DIFFERENTIAL DIAGNOSIS; MIDDLE AGED; PRECANCER; TIME;

ADULT; AGED; AGED, 80 AND OVER; DIAGNOSIS, DIFFERENTIAL; EARLY DETECTION OF CANCER; FEMALE; HUMANS; IMMUNOGLOBULINS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PARAPROTEINEMIAS; PRECANCEROUS CONDITIONS; PREVALENCE; TIME FACTORS;

EID: 67049162188     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-12-194241     Document Type: Article

References (22)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351:1860-1873.
2. Anonymous. Cancer Facts & Figures 2008. Atlanta, GA: American Cancer Society; 2008.
3. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354:1362-1369.
4. Anonymous. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749-757.
5. Kyle RA. Monoclonal gammopathy of undetermined significance: natural history in 241 cases. Am J Med. 1978;64:814-826.
6. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564-569. (Pubitemid 34438817)
7. Prorok PC, Andriole GL, Bresalier RS, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials. 2000;21:273S-309S.
8. Hayes RB, Sigurdson A, Moore L, et al. Methods for etiologic and early marker investigations in the PLCO trial. Mutat Res. 2005;592:147-154. (Pubitemid 41714051)
9. Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem. 2002;48:1437-1444.
10. Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood. 2001;97:2900-2902.
11. Kyle RA, Katzmann JA, Lust JA, Dispenzieri A. Immunochemical characterization of immunoglobulins. In: Rose NR, Hamilton RG, Detrik B, eds. Manual of Clinical Laboratory Immunology. Washington, DC: ASM Press; 2002:71-91.
12. Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106:812-817.
13. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42:121-130.
14. Kyle RA, Therneau TM, Rajkumar SV, et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood. 2003;102:3759-3764. (Pubitemid 37409398)
15. Landgren O, Gridley G, Turesson I, et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood. 2006;107:904-906. (Pubitemid 43156286)
16. Landgren O, Kyle RA. Multiple myeloma, chronic lymphocytic leukaemia and associated precursor diseases. Br J Haematol. 2007;139:717-723. (Pubitemid 350115730)
17. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood. 2005;106:296-303. (Pubitemid 40967205)
18. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer. 2002;2:175-187.
19. Zhan F, Barlogie B, Arzoumanian V, et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood. 2007;109:1692-1700. (Pubitemid 46239604)
20. Bladé J, Rosinol L, Cibeira MT, de Larrea CF. Pathogenesis and progression of monoclonal gammopathy of undetermined significance. Leukemia. 2008;22:1651-1657.
21. Rosiñol L, Cibeira MT, Montoto S, et al. Monoclonal gammopathy of undetermined significance: predictors of malignant transformation and recognition of an evolving type characterized by a progressive increase in M protein size. Mayo Clin Proc. 2007;82:428-434. (Pubitemid 46543466)
22. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood. 2004;104:607-618. (Pubitemid 38970551)